参与长春新碱药代动力学或药效学的基因多态性与白血病患儿运动功能受损无关。
Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
作者信息
Hartman A, van Schaik R H N, van der Heiden I P, Broekhuis M J C, Meier M, den Boer M L, Pieters R
机构信息
Department of Pediatric Oncology/Hematology, Erasmus MC Sophia Children's Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands.
出版信息
Leuk Res. 2010 Feb;34(2):154-9. doi: 10.1016/j.leukres.2009.04.027. Epub 2009 May 20.
INTRODUCTION
Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.
METHODS
Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.
RESULTS
Motor performance was not significantly affected by CYP3A53/3 and CYP3A513 genotypes, MDR-1 polymorphisms or MAPT haplotype.
CONCLUSION
Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.
引言
完成急性淋巴细胞白血病（ALL）治疗的儿童运动功能受损可能与代谢基因CYP3A5或长春新碱毒性相关基因MDR-1和MAPT的多态性有关。
方法
使用儿童运动评估量表（Movement-ABC）测量运动功能。对来自单核血细胞的DNA进行CYP3A5、MDR-1和MAPT多态性基因分型。
结果
CYP3A53/3和CYP3A513基因型、MDR-1多态性或MAPT单倍型对运动功能无显著影响。
结论
我们的数据未显示CYP3A5、MDR-1或MAPT多态性与ALL治疗后儿童运动功能受损有关。
Zotero 插件